Pneumonia
Conditions
Interventions
Infusing 200mg of Arbekacin sulfate diluted in 100ml of normal 0.9% saline solution in an hour. Amount of Arbekacin sulfate is adjusted to reach 20microg/ml of peak concentration.
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with intubation or tracheotomy suspected of MRSA pneumonia.
Exclusion criteria
Exclusion criteria: 1)History of hypersensitivity caused by lidocaine hydrochloride. 2)History of hypersensitivity caused by aminoglycoside antibiotics or bacitracin. 3)One who has family or patient's history of hearing loss caused by aminoglycoside antibiotics. One who has hearing loss caused by any other reasons. 4)Creatinine clearance <=30mL/min. 5)Smorker. 6)who can't undergo BMS because of bleeding tendency. 7)Any other participants whose condition is inappropriate for the evaluation of this clinical study, judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate PK in serum and ELF of Arbekacin sulfate, the ratio ELF:serum of Arbekacin sulfate. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate inflammatory cytokines (IL-1, IL-2, IL-6, IL-10, pro-calcitonine, etc) in serum after BMS. | — |
Countries
Japan
Contacts
Public ContactNaoki Hasegawa
Keio University Hospital, School of Medicine Infection Control Center
Outcome results
None listed